Your browser is no longer supported. Please, upgrade your browser.
Settings
FOLD Amicus Therapeutics, Inc. daily Stock Chart
FOLD [NASD]
Amicus Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.87 Insider Own0.80% Shs Outstand227.19M Perf Week-1.85%
Market Cap3.02B Forward P/E- EPS next Y-0.89 Insider Trans-17.02% Shs Float221.60M Perf Month0.23%
Income-349.10M PEG- EPS next Q-0.31 Inst Own- Short Float9.54% Perf Quarter13.49%
Sales91.20M P/S33.11 EPS this Y-0.50% Inst Trans0.42% Short Ratio6.47 Perf Half Y8.14%
Book/sh1.81 P/B7.34 EPS next Y25.20% ROA-42.00% Target Price18.80 Perf Year-6.47%
Cash/sh2.22 P/C5.99 EPS next 5Y- ROE-76.00% 52W Range8.27 - 17.62 Perf YTD38.73%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-49.50% 52W High-25.09% Beta1.81
Dividend %- Quick Ratio6.30 Sales past 5Y202.00% Gross Margin84.20% 52W Low59.61% ATR0.52
Employees508 Current Ratio6.40 Sales Q/Q121.80% Oper. Margin- RSI (14)47.83 Volatility5.27% 3.56%
OptionableYes Debt/Eq0.94 EPS Q/Q4.40% Profit Margin- Rel Volume0.33 Prev Close13.29
ShortableYes LT Debt/Eq0.94 EarningsMay 30 BMO Payout- Avg Volume3.26M Price13.20
Recom1.60 SMA20-2.96% SMA501.13% SMA2006.04% Volume679,339 Change-0.68%
Apr-05-19Initiated Janney Buy
Jan-30-19Initiated Cantor Fitzgerald Overweight $20
Oct-29-18Initiated Citigroup Neutral $12
Aug-17-18Downgrade Chardan Capital Markets Buy → Neutral $18 → $15
Oct-06-17Resumed Goldman Neutral
Sep-13-17Reiterated Chardan Capital Markets Buy $17.50 → $16.50
Aug-10-17Reiterated Chardan Capital Markets Buy $12.50 → $17.50
Jan-24-17Upgrade Robert W. Baird Neutral → Outperform $7 → $10
May-18-16Initiated BofA/Merrill Buy $10
Apr-14-16Initiated Robert W. Baird Neutral $9
Apr-12-16Reiterated Chardan Capital Markets Buy $10 → $15
Sep-16-15Downgrade Chardan Capital Markets Buy → Neutral $17
Jun-16-15Reiterated Chardan Capital Markets Buy $14 → $17.50
May-29-15Initiated Chardan Capital Markets Buy $14
Dec-20-12Reiterated Canaccord Genuity Buy $11 → $6
Dec-20-12Downgrade Capstone Investments Buy → Hold $3
Nov-01-12Initiated Capstone Investments Buy $7
Apr-06-10Initiated Canaccord Adams Buy
Mar-31-10Initiated Leerink Swann Mkt Perform
Oct-05-09Downgrade Wedbush Morgan Outperform → Underperform $17 → $3.50
Apr-15-19 03:36PM  FOLD Stock Could See a Surge Soon, Says Signal Schaeffer's Investment Research
12:00PM  Amicus Therapeutics to Present Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting GlobeNewswire
Apr-10-19 12:47PM  What Investors Should Know About Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Financial Strength Simply Wall St.
Apr-05-19 12:27PM  Janney: Amicus Therapeutics Has Significant Upside From Gene Therapy Pipeline Benzinga
Mar-30-19 09:30AM  Amicus Therapeutics (FOLD) Up 12.4% Since Last Earnings Report: Can It Continue? Zacks
Mar-29-19 07:10AM  Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-20-19 02:09PM  Edited Transcript of FOLD earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
07:00AM  Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200 GlobeNewswire
Mar-07-19 02:52PM  Amicus Therapeutics Looks Impressive If it Can Rally Above $18 TheStreet.com
Mar-06-19 02:39PM  Will Amicus Therapeutics, Inc.s (NASDAQ:FOLD) Earnings Grow In The Years Ahead? Simply Wall St.
Mar-01-19 11:59AM  Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018 Zacks +15.04%
Feb-28-19 12:04PM  Amicus Therapeutics Inc (FOLD) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates GlobeNewswire
06:30AM  Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-26-19 07:32AM  N.J. biotech firm expanding to Philadelphia, creating 200 new jobs American City Business Journals
07:00AM  Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia GlobeNewswire
Feb-25-19 09:02AM  What's in Store for Universal Health (UHS) Q4 Earnings? Zacks +5.87%
04:00AM  U.S. FDA Grants Breakthrough Therapy Designation (BTD) to Amicus AT-GAA in Late Onset Pompe Disease GlobeNewswire
Feb-22-19 04:36PM  What's in Store for Teladoc's (TDOC) Q4 Earnings? Zacks
Feb-21-19 10:31AM  Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Feb-20-19 09:32AM  Tenet Healthcare (THC) Q4 Earnings: What's in the Offing? Zacks
Feb-13-19 07:30AM  New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-12-19 07:00AM  Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019 GlobeNewswire
Feb-11-19 04:51PM  Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-05-19 04:01PM  Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium GlobeNewswire -5.22%
Feb-04-19 10:38AM  2 Small-Cap Stocks That Are Still a Bargain TheStreet.com
Jan-28-19 08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and ACADIA Pharmaceuticals ACCESSWIRE
Jan-24-19 10:08AM  Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition Zacks
Jan-18-19 07:00AM  Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium 2019 GlobeNewswire
Jan-16-19 08:05AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics ACCESSWIRE
Jan-15-19 09:00AM  Is Amicus Therapeutics' Sharp Reversal Warranted? Motley Fool +5.36%
Jan-10-19 07:30AM  Research Report Identifies FedEx, Amicus Therapeutics, National HealthCare, Allegion, Horizon Global, and PICO with Renewed Outlook  Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jan-07-19 07:00AM  Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance GlobeNewswire
Jan-03-19 04:01PM  Amicus Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
07:00AM  Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease GlobeNewswire
Dec-20-18 07:00AM  Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease GlobeNewswire -5.11%
Dec-19-18 04:01PM  Amicus Therapeutics Announces Executive Team Updates GlobeNewswire -6.47%
Dec-12-18 10:58AM  Should You Worry About Amicus Therapeutics, Inc.s (NASDAQ:FOLD) CEO Pay? Simply Wall St.
Dec-11-18 04:01PM  Amicus Therapeutics Awarded United Kingdom Prix Galien Medal for Galafold® (Migalastat) GlobeNewswire
07:05AM  Today's Research Reports on Trending Tickers: Immunomedics and Amicus Therapeutics ACCESSWIRE
Dec-10-18 03:21AM  Amicus Therapeutics, Inc. (FOLD) Hedge Funds Are Snapping Up Insider Monkey +6.96%
Dec-04-18 07:35AM  Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage Fundamental Analysis, Key Performance Indications GlobeNewswire -9.32%
Nov-29-18 07:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Amicus Therapeutics ACCESSWIRE
Nov-20-18 07:52AM  Edited Transcript of FOLD earnings conference call or presentation 5-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-14-18 06:55AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen ACCESSWIRE -5.01%
Nov-12-18 07:00AM  Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Nov-05-18 08:45AM  Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:42AM  Amicus Therapeutics: 3Q Earnings Snapshot Associated Press
07:00AM  Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates GlobeNewswire
Oct-29-18 08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Geron ACCESSWIRE
07:00AM  Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018 GlobeNewswire
Oct-25-18 09:25AM  Recent Analysis Shows PennyMac Mortgage Investment Trust, Amicus Therapeutics, Children's Place, PLDT, NanoString Technologies, and Worthington Industries Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +5.08%
Oct-22-18 01:56PM  5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout InvestorPlace
Oct-15-18 08:00AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Amicus Therapeutics ACCESSWIRE
Oct-11-18 07:00AM  Amicus Therapeutics to Host Analyst Day 2018 Today in New York City GlobeNewswire
Oct-08-18 07:00AM  Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies GlobeNewswire
Oct-05-18 07:00AM  Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study at 23rd International Annual Congress of the World Muscle Society GlobeNewswire
Oct-04-18 11:08AM  Amicus Therapeutics is looking to find a cure for rare diseases Yahoo Finance Video
08:44AM  Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 6.7% Zacks
Oct-02-18 07:00AM  Amicus Therapeutics Announces Presentation and Poster at the 23rd International Congress of the World Muscle Society GlobeNewswire
Sep-27-18 08:00AM  Today's Research Reports on Trending Tickers: Amarin and Amicus Therapeutics ACCESSWIRE
Sep-26-18 07:00AM  Amicus Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Sep-25-18 07:55AM  Report: Exploring Fundamental Drivers Behind Ocean Power Technologies, Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, Fanhua, and Parsley Energy New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Sep-24-18 02:21PM  Tavistock Restaurants to open new Lake Nona pizza and brew pub American City Business Journals
Sep-20-18 11:27AM  Why Amicus Therapeutics Is Up 10% Today Motley Fool +6.86%
07:41AM  [$$] Amicus to Acquire Gene Therapy Company Celenex The Wall Street Journal
06:00AM  Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders GlobeNewswire
Sep-19-18 02:38PM  7 Biotech Stocks to Buy Now InvestorPlace
Sep-14-18 02:36PM  See future biotech facility slated for Lake Nona (PHOTOS) American City Business Journals
Sep-13-18 05:26PM  Is Amicus Therapeutics choosing Orlando for high-wage biotech jobs site? Sure looks like it American City Business Journals
Sep-11-18 07:00AM  Amicus Therapeutics Announces Board Appointments GlobeNewswire
Sep-10-18 08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Intercept Pharmaceuticals ACCESSWIRE
07:00AM  Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease GlobeNewswire
Sep-06-18 04:05PM  Eateries, entertainment slated for $780M Lake Nona Town Center's 'Boxi Park' American City Business Journals -6.12%
Aug-31-18 01:19PM  Global biotech firm may add to growing Lake Nona presence American City Business Journals
07:00AM  Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2018 GlobeNewswire
Aug-21-18 11:05AM  Lake Nona may get global biotech firm to build facility, create 300+ high-wage jobs American City Business Journals
Aug-13-18 01:26PM  The Week Ahead: Nvidia, Retailer Earnings In Focus Benzinga -6.78%
10:16AM  Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold Zacks
09:04AM  Amicus sets $315,000 price for new Fabry disease treatment Reuters
08:28AM  Amicus sets $315,000 price for new Fabry disease treatment Reuters
Aug-12-18 04:52PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs Benzinga
Aug-10-18 05:50PM  Amicus Therapeutics receives U.S. approval for Fabry disease drug Reuters
04:05PM  FDA Approves Galafold (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease GlobeNewswire
Aug-07-18 09:20AM  Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates Zacks +7.28%
08:17AM  Amicus Therapeutics: 2Q Earnings Snapshot Associated Press
07:00AM  Amicus Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Updates GlobeNewswire
06:30AM  Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 03:35PM  Q2 Earnings Outlook For Amicus Therapeutics Benzinga
Jul-31-18 07:40AM  Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines Future Expectations, Projections Moving into 2018 GlobeNewswire
07:30AM  Amicus Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jul-30-18 08:00AM  Research Report Identifies General Dynamics, General Motors, Amicus Therapeutics, Drive Shack, Zoe's Kitchen, and Vishay Intertechnology with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM  Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks ACCESSWIRE
Jun-29-18 07:25AM  Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks ACCESSWIRE
Jun-27-18 11:32AM  All You Need To Know About Amicus Therapeutics Incs (NASDAQ:FOLD) Financial Health Simply Wall St.
08:14AM  Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics ACCESSWIRE
Jun-26-18 04:05PM  Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease GlobeNewswire
Jun-08-18 07:00AM  Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors GlobeNewswire
Jun-01-18 07:00AM  Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference GlobeNewswire
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barth JayChief Medical OfficerApr 05Option Exercise2.2950,000114,500179,767Apr 08 04:52 PM
Barth JayChief Medical OfficerApr 05Sale14.2050,000710,195129,767Apr 08 04:52 PM
Crowley John FChairman & CEOApr 01Option Exercise3.5020,00069,968688,081Apr 03 06:29 PM
Crowley John FChairman & CEOApr 01Sale13.6320,000272,626668,081Apr 03 06:29 PM
Crowley John FChairman & CEOMar 01Option Exercise3.5420,00070,848688,081Mar 05 05:47 PM
Crowley John FChairman & CEOMar 01Sale13.6020,000271,979668,081Mar 05 05:47 PM
Barth JayChief Medical OfficerFeb 25Option Exercise2.7070,000188,725173,497Feb 27 05:30 PM
Barth JayChief Medical OfficerFeb 25Sale12.5270,000876,134129,767Feb 27 05:30 PM
Crowley John FChairman & CEOFeb 01Option Exercise3.8220,00076,400688,081Feb 05 06:10 PM
Crowley John FChairman & CEOFeb 01Sale12.1220,000242,320668,081Feb 05 06:10 PM
Campbell Bradley LChief Operating OfficerJan 22Option Exercise10.3636,000372,960275,360Jan 24 05:06 PM
Campbell Bradley LChief Operating OfficerJan 22Sale11.8136,000425,135239,360Jan 24 05:06 PM
Do HungChief Science OfficerJan 16Option Exercise4.8235,024168,749474,937Jan 17 08:48 PM
Do HungChief Science OfficerJan 16Sale12.0536,669441,861438,268Jan 17 08:48 PM
Do HungChief Science OfficerJan 15Option Exercise3.958,20032,430456,513Jan 17 08:48 PM
Crowley John FChairman & CEOJan 15Option Exercise10.36103,5001,072,260771,581Jan 17 08:47 PM
Do HungChief Science OfficerJan 15Sale12.0016,600199,200439,913Jan 17 08:48 PM
Crowley John FChairman & CEOJan 15Sale11.71103,5001,212,296668,081Jan 17 08:47 PM
Baird William D IIIChief Financial OfficerOct 15Option Exercise2.4510,00024,500127,622Oct 17 06:28 PM
Baird William D IIIChief Financial OfficerOct 15Sale12.2310,000122,275117,622Oct 17 06:28 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 03Buy12.6930,000380,70020,724,424Oct 05 08:36 AM
PERCEPTIVE ADVISORS LLC10% OwnerSep 24Buy12.4520,000249,00020,694,424Oct 05 08:36 AM
PERCEPTIVE ADVISORS LLC10% OwnerSep 21Buy12.5350,000626,50020,674,424Sep 25 08:30 AM
PERCEPTIVE ADVISORS LLC10% OwnerSep 13Buy11.74100,0001,174,00020,624,424Sep 17 08:22 AM
PERCEPTIVE ADVISORS LLC10% OwnerSep 12Buy12.00500,0006,001,50020,524,424Sep 14 08:30 AM
Andrews Kurt J.SVP, Human ResourcesJul 02Option Exercise6.135,00030,65040,469Jul 05 04:25 PM
Baird William D IIIChief Financial OfficerJul 02Option Exercise2.4510,00024,500117,622Jul 05 04:27 PM
Andrews Kurt J.SVP, Human ResourcesJul 02Sale15.635,00078,16635,469Jul 05 04:25 PM
Baird William D IIIChief Financial OfficerJul 02Sale15.6310,000156,292107,622Jul 05 04:27 PM
Do HungChief Science OfficerJun 01Sale16.7225,000418,000396,771Jun 04 05:18 PM
MCGLYNN MARGARET GDirectorMay 16Option Exercise3.3210,00033,20025,814May 18 06:07 PM
Do HungChief Science OfficerMay 16Sale15.0025,000375,000421,771May 16 06:22 PM
MCGLYNN MARGARET GDirectorMay 16Sale16.0010,000160,00015,814May 18 06:07 PM
Barth JayChief Medical OfficerMay 14Option Exercise2.295,00011,45090,409May 15 07:37 PM
Barth JayChief Medical OfficerMay 14Sale14.045,00070,22385,409May 15 07:37 PM